Progress in biopharmaceutical development

被引:232
作者
Kesik-Brodacka, Malgorzata [1 ]
机构
[1] Inst Biotechnol & Antibiot, Dept Bioengn, Staroscinska 5, PL-02516 Warsaw, Poland
关键词
biobetter; biopharmaceutical; biosimilar; drug market; monoclonal antibodies; recombinant vaccines; TRANSGENIC PROTEIN-PRODUCTION; CYTOCHROME-P450; BM3; BISPECIFIC ANTIBODIES; TRASTUZUMAB EMTANSINE; NEXT-GENERATION; GENE-THERAPY; BIOSIMILARS; VACCINE; FUTURE; IDENTIFICATION;
D O I
10.1002/bab.1617
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.
引用
收藏
页码:306 / 322
页数:17
相关论文
共 131 条
[81]  
Morrison C., 2015, TRADESECRETS
[82]   Production of Recombinant Proteins in Milk of Transgenic and Non-transgenic Goats [J].
Moura, Raylene Ramos ;
Melo, Luciana Magalhaes ;
de Figueiredo Freitas, Vicente Jose .
BRAZILIAN ARCHIVES OF BIOLOGY AND TECHNOLOGY, 2011, 54 (05) :927-938
[83]  
Müller D, 2007, CURR OPIN MOL THER, V9, P319
[84]   Bispecific antibodies for cancer immunotherapy: Current perspectives [J].
Müller D. ;
Kontermann R.E. .
BioDrugs, 2010, 24 (2) :89-98
[85]  
Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1
[86]   A review of blinatumomab, a novel immunotherapy [J].
Newman, Matthew J. ;
Benani, Dina J. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (04) :639-645
[87]   Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections [J].
Nuccitelli, Annalisa ;
Cozzi, Roberta ;
Gourlay, Louise J. ;
Donnarumma, Danilo ;
Necchi, Francesca ;
Norais, Nathalie ;
Telford, John L. ;
Rappuoli, Rino ;
Bolognesi, Martino ;
Maione, Domenico ;
Grandi, Guido ;
Rinaudo, C. Daniela .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (25) :10278-10283
[88]  
Ortiz de Montellano P. R., 2005, Cytochrome P450: Structure, Mechanism, and Biochemistry, DOI DOI 10.1007/B139087
[89]   An immunogenic personal neoantigen vaccine for patients with melanoma [J].
Ott, Patrick A. ;
Hu, Zhuting ;
Keskin, Derin B. ;
Shukla, Sachet A. ;
Sun, Jing ;
Bozym, David J. ;
Zhang, Wandi ;
Luoma, Adrienne ;
Giobbie-Hurder, Anita ;
Peter, Lauren ;
Chen, Christina ;
Olive, Oriol ;
Carter, Todd A. ;
Li, Shuqiang ;
Lieb, David J. ;
Eisenhaure, Thomas ;
Gjini, Evisa ;
Stevens, Jonathan ;
Lane, William J. ;
Javeri, Indu ;
Nellaiappan, Kaliappanadar ;
Salazar, Andres M. ;
Daley, Heather ;
Seaman, Michael ;
Buchbinder, Elizabeth I. ;
Yoon, Charles H. ;
Harden, Maegan ;
Lennon, Niall ;
Gabriel, Stacey ;
Rodig, Scott J. ;
Barouch, Dan H. ;
Aster, Jon C. ;
Getz, Gad ;
Wucherpfennig, Kai ;
Neuberg, Donna ;
Ritz, Jerome ;
Lander, Eric S. ;
Fritsch, Edward F. ;
Hacohen, Nir ;
Wu, Catherine J. .
NATURE, 2017, 547 (7662) :217-+
[90]   Robust production of recombinant phosphoproteins using cell-free protein synthesis [J].
Oza, Javin P. ;
Aerni, Hans R. ;
Pirman, Natasha L. ;
Barber, Karl W. ;
ter Haar, Charlotte M. ;
Rogulina, Svetlana ;
Amrofell, Matthew B. ;
Isaacs, Farren J. ;
Rinehart, Jesse ;
Jewett, Michael C. .
NATURE COMMUNICATIONS, 2015, 6